Toxin News and Research

RSS

NIAID awards $6.25M to Profectus to optimize portfolio of genetic adjuvants

Profectus BioSciences, Inc., a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases, today announced that it has received $6.25M in National Institute of Allergy and Infectious Disease (NIAID) grants and contracts.

8 Oct 2010

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.

6 Oct 2010

Study on resistance of harmful bacteria to antibiotics

A study by two Florida State University biochemists makes an important contribution to science's understanding of a serious problem causing concern worldwide: the growing resistance of some harmful bacteria to the drugs that were intended to kill them.

6 Oct 2010

USPTO approves Microdroplet botulinum toxin treatment

The patent application for Microdroplet botulinum toxin, a treatment that improves facial features without detracting from facial expressiveness, has been allowed to inventor Dr. Kenneth D. Steinsapir, M.D. on September 2, 2010.

5 Oct 2010

New method for detecting spores of non-proteolytic Clostridium botulinum

The Institute of Food Research has collaborated in the development of a new method for detecting spores of non-proteolytic Clostridium botulinum. This bacterium is the major health hazard associated with refrigerated convenience foods, and these developments give the food industry and regulators more quantitative information on which to base the procedures that ensure food safety.

1 Oct 2010

Health Canada approves Meridian Bioscience's illumigene C. difficile molecular amplification assay

Meridian Bioscience, Inc., today announced that it has received an approved medical device license from Health Canada for its new molecular amplification assay, illumigene C. difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon.

1 Oct 2010

Yoga, Tai Chi effective in treating fibromyalgia

This syndrome is often accompanied by fatigue, bowel disturbances, and urinary difficulty. Fibromyalgia can affect your daily activity, your sleep, and even your thinking when you're worn out and experiencing "brain fog." That's a term used by Henri Roca, MD, Medical Director at Greenwich Hospital's Center for Integrative Medicine in Cos Cob, Connecticut.

24 Sep 2010

Researchers load biological molecules onto 'nanosprings'

Researchers at Oregon State University have reported the successful loading of biological molecules onto "nanosprings" - a type of nanostructure that has gained significant interest in recent years for its ability to maximize surface area in microreactors.

17 Sep 2010

New anti-pathogenic drugs render MRSA harmless without killing bacteria

Menachem Shoham, PhD, associate professor and researcher in the department of biochemistry at the Case Western Reserve University School of Medicine, has identified new anti-pathogenic drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) harmless by preventing the production of toxins that cause disease.

17 Sep 2010

ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010

ViroPharma Incorporated today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections, a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.

16 Sep 2010

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Progenics Pharmaceuticals, Inc. today presented preclinical findings for its humanized monoclonal antibodies against the disease-causing toxins produced by the bacterium Clostridium difficile.

14 Sep 2010

Earthy or musty odors along with cyanobacteria may indicate presence of harmful cyanotoxins in lakes

Earthy or musty odors, along with visual evidence of blue-green algae, also known as cyanobacteria, may serve as a warning that harmful cyanotoxins are present in lakes or reservoirs. In a newly published USGS study of cyanobacterial blooms in Midwest lakes, taste-and-odor compounds were found almost every time cyanotoxins were found, indicating odor may serve as a warning that harmful toxins are present.

14 Sep 2010

Tikcro reports $3.2 million net loss for second-quarter 2010

Tikcro Technologies Ltd. today reported results for the second quarter and six months ended June 30, 2010.

7 Sep 2010

Research on bacterial cells may offer new hope for MRSA infection treatment

Selfish bacterial cells that act in their own interests and do not cooperate with their infection-causing colleagues can actually reduce the severity of infection.

7 Sep 2010

Murad launches Hydro-Dynamic Ultimate Moisture for dry, dehydrated skin

Murad, Inc. has announced the launch of Hydro-Dynamic Ultimate Moisture, an uber-rich, all purpose moisturizer that combines an extraordinarily luxurious recipe of ingredients to quench dry, dehydrated skin and restore youthful resilience and tone.

3 Sep 2010

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Taking a dietary supplement of organic zinc and the enzyme phytase four days before receiving botulinum toxin injections made the toxin more effective in 93 percent of patients tested in a recent study at The Methodist Hospital in Houston.

2 Sep 2010

Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing.

2 Sep 2010

Neutralizing key toxin associated with Staph aureus bacteria reduces severity of skin and soft-tissue damage

Scientists from the National Institutes of Health and University of Chicago have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated Staphylococcus aureus infections in the United States.

2 Sep 2010

Researchers find new fusion protein for E.coli bacterium vaccine development

South Dakota State University research is exploring a "fusion strategy" for making improved vaccines to protect pigs and humans against some strains of E. coli.

2 Sep 2010

Research on trypanosomes can open way for African sleeping sickness drug development

Trypanosomes are parasites responsible for many human and animal diseases, primarily in tropical climates. One disease these parasites cause, African sleeping sickness, results from the bite of infected tsetse flies, putting over 60 million Africans at risk in 36 sub-Saharan countries. The recent 1998-2001 sleeping sickness epidemics in South Sudan, Angola, Democratic Republic of Congo and Uganda killed tens of thousands of people and resulted in over a half million infected individuals.

31 Aug 2010